KORU Medical Systems, Inc. (NASDAQ:KRMD) Given Consensus Recommendation of “Moderate Buy” by Analysts

KORU Medical Systems, Inc. (NASDAQ:KRMD) has been given a consensus rating of “Moderate Buy” by the five brokerages that are covering the company, MarketBeat reports. One investment analyst has rated the stock with a sell recommendation and four have assigned a buy recommendation to the company. The average 1-year target price among brokerages that have issued ratings on the stock in the last year is $7.25.

A number of equities analysts have recently issued reports on KRMD shares. Wall Street Zen raised KORU Medical Systems from a “hold” rating to a “buy” rating in a report on Saturday, July 4th. Weiss Ratings upgraded KORU Medical Systems from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Thursday, July 30th.

Insider Activity

In related news, insider Adam R. Kalbermatten acquired 12,500 shares of the business’s stock in a transaction on Thursday, June 11th. The stock was bought at an average cost of $3.94 per share, with a total value of $49,250.00. Following the completion of the acquisition, the insider owned 312,500 shares in the company, valued at $1,231,250. The trade was a 4.17% increase in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Insiders acquired 28,000 shares of company stock worth $109,430 over the last three months. 18.50% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On KORU Medical Systems

Hedge funds have recently made changes to their positions in the company. Bank of America Corp DE lifted its holdings in KORU Medical Systems by 36.0% during the 1st quarter. Bank of America Corp DE now owns 37,971 shares of the company’s stock valued at $164,000 after purchasing an additional 10,045 shares during the last quarter. Royal Bank of Canada grew its stake in KORU Medical Systems by 77.3% during the first quarter. Royal Bank of Canada now owns 235,804 shares of the company’s stock worth $1,019,000 after buying an additional 102,800 shares during the last quarter. Vivaldi Capital Management LP grew its stake in KORU Medical Systems by 51.6% during the first quarter. Vivaldi Capital Management LP now owns 29,885 shares of the company’s stock worth $129,000 after buying an additional 10,172 shares during the last quarter. Renaissance Technologies LLC acquired a new stake in shares of KORU Medical Systems during the first quarter worth approximately $198,000. Finally, Arrowstreet Capital Limited Partnership acquired a new stake in shares of KORU Medical Systems during the first quarter worth approximately $79,000. Institutional investors and hedge funds own 58.60% of the company’s stock.

KORU Medical Systems Stock Performance

NASDAQ:KRMD opened at $4.13 on Thursday. The company has a 50-day moving average of $4.13 and a 200-day moving average of $4.39. KORU Medical Systems has a 52 week low of $3.20 and a 52 week high of $6.61. The company has a market capitalization of $189.70 million, a price-to-earnings ratio of -82.60 and a beta of 0.45.

KORU Medical Systems (NASDAQ:KRMD) last posted its quarterly earnings results on Wednesday, August 5th. The company reported $0.01 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.02) by $0.03. The firm had revenue of $12.05 million during the quarter, compared to analyst estimates of $11.62 million. KORU Medical Systems had a negative net margin of 5.27% and a negative return on equity of 13.61%. Sell-side analysts forecast that KORU Medical Systems will post -0.04 EPS for the current year.

About KORU Medical Systems

KORU Medical Systems, Inc develops and manufactures medical devices and supplies in the United States and internationally. It offers the freedom infusion systems to deliver life-saving therapies to patients with chronic illnesses, such as primary immunodeficiency diseases, chronic inflammatory demyelinating polyneuropathy, and paroxysmal nocturnal hemoglobinuria. Its products include the FREEDOM60 syringe infusion system, the FreedomEdge syringe driver, HIgH-Flo subcutaneous safety needle sets, and precision flow rate tubing products.